Welcome to our dedicated page for Nexalin Tech news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Nexalin Technology announced that its new division, Nexalin America, has joined the National Traumatic Brain Injury (TBI) Registry Coalition. This Coalition comprises private sector and non-profit organizations dedicated to advancing research, raising awareness, and supporting clinical trials for TBI, affecting millions annually. Members include the NFL Players Association, Spaulding Rehabilitation at Mass General, United States Brain Injury Alliance, Abbott, and American Academy of Neurology. Nexalin America will leverage its neurostimulation technology expertise to contribute to developing a national TBI registry. CEO Mark White highlighted this partnership as a significant step towards combating brain injuries through advanced technology and collaborative research.
Nexalin Technology, Inc. is hosting an exclusive live investor webinar on May 23, 2024, featuring CEO Mark White discussing the company's clinical data on its deep brain stimulation device and new clinic model. Investors can register for the event and submit questions online.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.